These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 3144163)
1. Encainide for treatment of atrioventricular reciprocating tachycardia in the Wolff-Parkinson-White syndrome. Miles WM; Zipes DP; Rinkenberger RL; Markel ML; Prystowsky EN; Dougherty AH; Heger JJ; Naccarelli GV Am J Cardiol; 1988 Dec; 62(19):20L-25L. PubMed ID: 3144163 [TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy and electrophysiologic effects of encainide in patients with Wolff-Parkinson-White syndrome. Prystowsky EN; Klein GJ; Rinkenberger RL; Heger JJ; Naccarelli GV; Zipes DP Circulation; 1984 Feb; 69(2):278-87. PubMed ID: 6418407 [TBL] [Abstract][Full Text] [Related]
3. Encainide for atrial fibrillation associated with Wolff-Parkinson-White syndrome. Rinkenberger RL; Naccarelli GV; Miles WM; Markel ML; Dougherty AH; Prystowsky EN; Heger JJ; Zipes DP Am J Cardiol; 1988 Dec; 62(19):26L-30L. PubMed ID: 3144164 [TBL] [Abstract][Full Text] [Related]
4. Encainide for treatment of supraventricular tachycardias associated with the Wolff-Parkinson-White syndrome. Markel ML; Prystowsky EN; Heger JJ; Miles WM; Fineberg N; Zipes DP Am J Cardiol; 1986 Aug; 58(5):41C-48C. PubMed ID: 3092619 [TBL] [Abstract][Full Text] [Related]
5. Electrophysiologic and clinical effects of intravenous and oral encainide in accessory atrioventricular pathway. Kunze KP; Kuck KH; Schlüter M; Kuch B; Bleifeld W Am J Cardiol; 1984 Aug; 54(3):323-9. PubMed ID: 6431796 [TBL] [Abstract][Full Text] [Related]
6. Role of adrenergic stimulation by isoproterenol in reversal of effects of encainide in supraventricular tachycardia. Akhtar M; Niazi I; Naccarelli GV; Tchou P; Rinkenberger R; Dougherty AH; Jazayeri M Am J Cardiol; 1988 Dec; 62(19):45L-49L. PubMed ID: 3144167 [TBL] [Abstract][Full Text] [Related]
7. Electrophysiologic and clinical effects of intravenous and oral encainide in patients with Wolff-Parkinson-White syndrome and paroxysmal atrial fibrillation. Chimienti M; Moizi M; Salerno JA; Klersy C; Guasti L; Previtali M; Marangoni E; Montemartini C; Bobba P Eur Heart J; 1987 Mar; 8(3):282-90. PubMed ID: 3107987 [TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and electrophysiologic effects of intravenous and oral encainide in patients with accessory atrioventricular pathways and supraventricular arrhythmias. Abdollah H; Brugada P; Green M; Wehr M; Wellens HJ Am J Cardiol; 1984 Sep; 54(6):544-9. PubMed ID: 6433688 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and electrophysiologic effects of encainide for atrioventricular nodal reentrant tachycardia. Naccarelli GV; Jackman WM; Akhtar M; Rinkenberger RL; Friday KJ; Dougherty AH; Tchou P; Yeung-Lai-Wah JA Am J Cardiol; 1988 Dec; 62(19):31L-36L. PubMed ID: 3144165 [TBL] [Abstract][Full Text] [Related]
10. [Clinical electrophysiologic effects of lorcainide in patients and its effect on the conduction of accessory pathway in Wolff-Parkinson-White syndrome]. Jiang H Zhonghua Xin Xue Guan Bing Za Zhi; 1990 Jun; 18(3):157-9, 190. PubMed ID: 2086169 [TBL] [Abstract][Full Text] [Related]
11. Electrophysiology of oral encainide. Jackman WM; Zipes DP; Naccarelli GV; Rinkenberger RL; Heger JJ; Prystowsky EN Am J Cardiol; 1982 Apr; 49(5):1270-8. PubMed ID: 6801954 [TBL] [Abstract][Full Text] [Related]
12. Encainide for resistant supraventricular tachycardia in children: follow-up report. Strasburger JF; Smith RT; Moak JP; Gothing C; Garson A Am J Cardiol; 1988 Dec; 62(19):50L-54L. PubMed ID: 3144168 [TBL] [Abstract][Full Text] [Related]
13. Electrophysiologic and clinical effects of oral encainide in paroxysmal atrioventricular node reentrant tachycardia. Chimienti M; Li Bergolis M; Moizi M; Salerno JA J Am Coll Cardiol; 1989 Oct; 14(4):992-8. PubMed ID: 2507613 [TBL] [Abstract][Full Text] [Related]
14. Electrophysiologic and antiarrhythmic effects of oral encainide in patients with atrioventricular nodal reentry or nodoventricular reentry. Miles WM; Chang MS; Heger JJ; Rinkenberger RL; Zipes DP; Prystowsky EN Am Heart J; 1987 Jul; 114(1 Pt 1):26-33. PubMed ID: 3111237 [TBL] [Abstract][Full Text] [Related]
15. Effect of propafenone in the Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up. Breithardt G; Borggrefe M; Wiebringhaus E; Seipel L Am J Cardiol; 1984 Nov; 54(9):29D-39D. PubMed ID: 6496367 [TBL] [Abstract][Full Text] [Related]
16. Electrophysiologic effects of lorcainide on the accessory pathway in the Wolff-Parkinson-White syndrome. Kasper W; Treese N; Meinertz T; Jähnchen E; Pop T Am J Cardiol; 1983 Jun; 51(10):1618-22. PubMed ID: 6858867 [TBL] [Abstract][Full Text] [Related]
17. Propofol has no direct effect on sinoatrial node function or on normal atrioventricular and accessory pathway conduction in Wolff-Parkinson-White syndrome during alfentanil/midazolam anesthesia. Sharpe MD; Dobkowski WB; Murkin JM; Klein G; Yee R Anesthesiology; 1995 Apr; 82(4):888-95. PubMed ID: 7717560 [TBL] [Abstract][Full Text] [Related]
18. Usefulness of programmed stimulation in predicting efficacy of propafenone in long-term antiarrhythmic therapy for paroxysmal supraventricular tachycardia. Manz M; Steinbeck G; Lüderitz B Am J Cardiol; 1985 Oct; 56(10):593-7. PubMed ID: 4050693 [TBL] [Abstract][Full Text] [Related]
19. Use of intracardiac recordings to determine the site of drug action in paroxysmal supraventricular tachycardia. Jackman WM; Friday KJ; Fitzgerald DM; Yeung-Lai-Wah JA; Lazzara R Am J Cardiol; 1988 Dec; 62(19):8L-19L. PubMed ID: 3059792 [TBL] [Abstract][Full Text] [Related]
20. Effect of atropine and isoproterenol on tachycardia induction in asymptomatic patients with Wolff-Parkinson-White electrocardiographic pattern. Kim YH; Leitch JW; Klein GJ; Yee R; Leather RA Can J Cardiol; 1992 Sep; 8(7):716-20. PubMed ID: 1422992 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]